High expression of the circadian clock gene NPAS2 is associated with progression and poor prognosis of gastric cancer: A single-center study

Table 1 Correlation between clinicopathological characteristic and NPAS2 in gastric cancer

Characteristic	Low expression of NPAS2	High expression of NPAS2	P value
Number	35	66
Age, n (%)			0.599
< 60	21 (60.0)	36 (54.5)
≥ 60	14 (40.0)	30 (45.5)
Sex, n (%)			0.626
Female	7 (20.0)	16 (24.2)
Male	28 (80.0)	51 (75.8)
TNM stage, n (%)			0.001
I-II	25 (71.4)	11 (16.7)
III-IV	10 (28.6)	55 (83.3)
pT stage, n (%)			0.351
T1-T2	6 (17.1)	29 (82.9)
T3-T4	7 (10.6)	59 (89.4)
pN stage, n (%)			0.009
N0	16 (45.7)	12 (18.2)
N1-N3	19 (54.3)	54 (81.8)
Metastasis, n (%)			0.032
M0	35 (100.0)	58 (87.9)
M1	0 (0.0)	8 (12.1)
Tumor size, n (%)			0.626
< 5	15 (42.9)	25 (37.9)
≥ 5	20 (57.1)	41 (62.1)
Tumor location, n (%)			0.611
Antrum	14 (40.0)	33 (50.0)
Body	9 (25.7)	13 (19.7)
Cardia	12 (34.3)	20 (30.3)
Venous invasion, n (%)			0.012
Negative	9 (25.7)	5 (7.6)
Positive	26 (74.3)	61 (92.4)
Neural invasion, n (%)			0.736
Negative	15 (42.9)	26 (39.4)
Positive	20 (57.1)	40 (60.6)
Lymphatic invasion, n (%)			0.001
Negative	22 (62.9)	12 (18.2)
Positive	13 (37.1)	54 (81.8)
Positive lymph node, n (%)			0.001
Negative	22 (62.9)	14 (21.2)
Positive	13 (37.1)	52 (78.8)
Differentiated degree, n (%)			0.16
Poorly	27 (77.1)	58 (87.9)
Moderately and highly	8 (22.9)	8 (12.1)
Lauren’s Classification, n (%)			0.569
Intestinal	23 (65.7)	47 (71.2)
Diffuse	12 (34.3)	19 (28.8)

pT stage: Pathological assessment of primary tumor; pN stage: Pathological assessment of regional lymph nodes; TNM: Tumor-node-metastasis.

Table 2 Univariate and multivariate Cox analysis of clinicopathological factors associated with the overall survival of gastric cancers

Characteristics	Univariate analysis		Multivariate analysis
	Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
Age
< 60	1
≥ 60	1.33 (0.82-2.17)	0.25
Gender
Female	1
Male	1.13 (0.63-2.05)	0.679
TNM stage
I-II	1
III-IV	7.07 (3.47-14.41)	< 0.001	3.61 (1.37-9.49)	0.009
pT stage
T1-T2	1
T3-T4	1.87 (0.81-4.35)	0.143
pN stage
N0	1
N1-N3	1.72 (1.38-2.15)	< 0.001	1.66 (0.68-4.07)	0.265
Metastasis
M0	1
M1	4.85 (2.24-10.46)	< 0.001	3.07 (1.33-7.1)	0.009
Tumor size
< 5	1
≥ 5	1.63 (0.97-2.72)	0.063
Tumor location
Antrum	1
Body	0.92 (0.53-1.60)	0.76
Cardia	1.13 (0.58-2.23)	0.72
Venous invasion
Negative	1
Positive	5.01 (1.57-15.98)	0.007	1.69 (0.49-5.84)	0.409
Neural invasion
Negative	1
Positive	1.73 (1.03-2.9)	0.037	1.71 (0.98-3)	0.06
Lymphatic invasion
Negative	1
Positive	3.53 (1.88-6.64)	< 0.001	0.39 (0.09-1.77)	0.225
Positive lymph node
Negative
Positive	3.35 (1.82-6.18)	< 0.001	2.23 (0.58-8.49)	0.241
Differentiated degree
Moderately and highly	1
Poorly	0.62 (0.29-1.30)	0.203
Lauren’s Classification
Diffuse type	1
Intestinal type	0.97 (0.57-1.64)	0.908
	0.97 (0.57-1.64)
NPAS2 expression
Low	1
High	5.13 (2.6-10.13)	< 0.001	2.43 (1.15-5.13)	0.020

pT stage: Pathological assessment of primary tumor; pN stage: Pathological assessment of regional lymph nodes; TNM: Tumor-node-metastasis.